

NDA 20-734/S-003

Baxter Healthcare Corporation
Attention: Marcia Marconi
Vice President Regulatory Affairs
Route 120 and Wilson Road
Round Lake, IL 60073

Dear Ms. Marconi:

Please refer to your supplemental new drug application dated June 30, 1999, received July 1, 1999, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for ClinimixTM sulfite-free (Amino Acid in Dextrose) Injections in ClarityTM Dual Chamber Container.

We acknowledge receipt of your submissions dated March 28 and 31, 2000.

This supplemental new drug application provides for changes in the WARNINGS, PRECATUIONS, and DOSAGE AND ADMINISTRATION sections in the package insert labeling in response to the Final Rule published in the Federal Register on December 13, 1994, titled *"Specific Requirements on Content and Format of labeling for Human Prescription Drugs: Revision of Pediatric Use Subsection in the Labeling"*, vol. 59, No. 238, Pages 64240-64250.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted March 28, 2000).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-734/S-003." Approval of this submission by FDA is not required before the labeling is used.

NDA 20-734/S-003

Page 2

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steve McCort, Regulatory Project Manager, at (301) 827-6415.

Sincerely,

John K. Jenkins, M.D.
Acting Director
Division of Metabolic and
Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

